Marcel Tongo

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 155 citations

Open Label, Week 96, Treatment And Prevention +10

Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon

Avelin F. Aghokeng, Eitel Mpoudi‐Ngolé, Henriette Thérèse Dimodi et al. · PLoS ONE · 2009 · 84 citations · Full text

HIV Infection in Rural Villages of Cameroon

Phillipe N. Nyambi, Léopold Zekeng, Henriette Kenfack et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2002 · 51 citations

HIV Type 1 Group M Clades Infecting Subjects From Rural Villages in Equatorial Rain Forests of Cameroon

Ping Zhong, Sherri Burda, Mateusz M. Urbanski et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2002 · 47 citations

High Degree of HIV-1 Group M (HIV-1M) Genetic Diversity within Circulating Recombinant Forms: Insight into the Early Events of HIV-1M Evolution

Marcel Tongo, Jeffrey R. Dorfman, Darren P. Martin · Journal of Virology · 2015 · 46 citations · Full text

Hiv-1m Evolution, Genetics, Genetic Epidemiology +20